NeoPharm (092730) Fundamentals 2026 — P/E 9.9x, Revenue Analysis | SniperIQ
NeoPharm (092730) is a KR-listed Consumer Defensive company in Household & Personal Products with a market capitalization of ₩291.4B, trading at ₩18630.00 on the KOE. This SniperIQ fundamentals page covers NeoPharm's valuation (P/E 9.9x, P/B 1.6x), profitability (net margin 21.4%), revenue (₩132.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is NeoPharm's market cap?
NeoPharm (092730) has a market capitalization of approximately ₩291.4B, trading at ₩18630.00 on the KOE. Market cap moves with the live share price.
What is NeoPharm's P/E ratio?
NeoPharm's trailing twelve-month P/E ratio is 9.9x, with a price-to-book (P/B) of 1.6x. Valuation multiples are best compared with Consumer Defensive sector peers rather than read in isolation.
How profitable is NeoPharm?
NeoPharm runs a net profit margin of 21.4%, a gross margin of 65.3%, and an operating margin of 21.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does NeoPharm generate?
NeoPharm reported revenue of ₩132.2B for fiscal year 2025, with net income of ₩27.9B and earnings per share (EPS) of 1778.81. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does NeoPharm pay a dividend?
NeoPharm offers a trailing dividend yield of about 3.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is NeoPharm financially healthy?
NeoPharm carries a debt-to-equity ratio of 0.01x and a current ratio of 5.75x, with a market beta of 0.22. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is NeoPharm a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For NeoPharm (092730) the key facts are: market cap ₩291.4B, P/E 9.9x, revenue ₩132.2B, 52-week range 15590-22650. Weigh valuation, profitability, growth, and balance-sheet strength against Consumer Defensive peers and form your own view.
Track NeoPharm's full fundamentals live
Get NeoPharm's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.